Expertise in
29
conditions

Dr. Irl Greenwell

Hematology | Oncology
Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
Offers Telehealth
Expertise in
29
conditions
Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 

Overview

Irl Greenwell is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Greenwell is highly rated in 29 conditions, according to our data. His top areas of expertise are Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Reticulohistiocytoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in SC

Hospital Affiliations

Roper St Francis Hospital-Berkeley Inc
Roper Hospital
Mount Pleasant Hospital
Bon Secours-St Francis Xavier Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, Charleston, SC 29414
Other Locations
Charleston Oncology-Downtown
125 Doughty St Ste 500, Charleston, SC 29403

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Enrollment Status: Suspended
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drugs: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral Azacitidine
Study Phase: Phase 2
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Ibrutinib
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Other, Biological
Study Drug: AB-205
Study Phase: Phase 3
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
View 5 Less Clinical Trials

13 Total Publications

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.
Journal: Blood advances
Published: September 24, 2025
Similar Doctors
Expertise in
37
conditions
Dr. Robert Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert Stuart
Hematology | Oncology

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (5.7 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
77
conditions
Dr. David Ellison
Hematology | Oncology
Expertise in
77
conditions
Dr. David Ellison
Hematology | Oncology

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
 (0.1 miles away)
843-577-6957
Languages Spoken:
English
See accepted insurances

David Ellison is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Ellison is highly rated in 77 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), WT1-Related Wilms Tumor Syndromes, and Gastrostomy.

Expertise in
30
conditions
Dr. Gene Saylors
Hematology | Oncology
Expertise in
30
conditions
Dr. Gene Saylors
Hematology | Oncology

Charleston Hematology Oncology Associates PA

2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
 (0.1 miles away)
843-577-6957
Languages Spoken:
English
See accepted insurances

Gene Saylors is a Hematologist and an Oncologist in Charleston, South Carolina. Dr. Saylors is highly rated in 30 conditions, according to our data. His top areas of expertise are Lung Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Pancreatectomy.

Frequently Asked Questions about Dr. Irl Greenwell

How do I make an appointment with Dr. Irl Greenwell?

You can book an appointment with Dr. Irl Greenwell by calling their office at 843-577-6957. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Irl Greenwell a top-rated expert for Marginal Zone Lymphoma (MZL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Irl Greenwell is classified as an Distinguished expert for Marginal Zone Lymphoma (MZL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Irl Greenwell specialize in?

While Dr. Irl Greenwell is a Hematology, they have specific expertise in Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Irl Greenwell participate in research or clinical trials?

Yes. Dr. Irl Greenwell has published 13 articles and abstracts on conditions like Marginal Zone Lymphoma (MZL). You can view a list of Dr. Irl Greenwell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Irl Greenwell accept my insurance?

Dr. Irl Greenwell accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-577-6957 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Greenwell's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile